Artificial Intelligence in Inherited Epidermolysis Bullosa: Current Evidence, Challenges, and Future Directions.

Epidermolysis bullosa (EB) comprises a group of rare inherited genodermatoses characterized by fragility and blistering of the skin and mucous membranes, chronic wounding, and significant morbidity including increased risk of squamous cell carcinoma in severe subtypes. Key unmet priorities include reducing diagnostic latency, establishing objective wound monitoring, enabling early detection of malignant transformation within chronic ulcerations, and developing therapies that durably modify disease progression. Artificial intelligence (AI) encompassing machine learning (ML), and deep learning (DL) is increasingly integrated into EB research and clinical practice to address these unmet needs. This structured narrative review synthesises current evidence on AI applications in EB spanning genetic diagnostics, wound assessment, inflammatory endotyping, drug repurposing, and emerging therapeutic technologies, and integrates evidence from registered clinical trials. In genomics, DL-based splicing prediction models and variant prioritisation frameworks accelerate pathogenic variant detection and reduce diagnostic latency. In wound care, convolutional neural networks-based platforms enable automated lesion segmentation and remote monitoring, while multimodal AI models predict healing trajectories and support stratification of wounds by chronicity. Computational transcriptomic analyses have identified candidate repurposing agents by reversing pathogenic gene expression signatures in EB tissue. Emerging convergence of AI with biosensors-integrated wound dressings and three-dimensional bioprinting of genetically corrected skin substitutes represents a transformative future direction. Translational barriers include limited EB-specific training datasets, algorithmic bias across diverse skin phototypes, the interpretability deficit of DL systems, and evolving regulatory frameworks for AI as a medical device. Expansion of internationally interoperable EB disease registries with standardised wound imaging protocols is identified as the single most impactful intervention to accelerate AI adoption. A minimum endpoint set for AI-assisted EB wound assessment, incorporating wound area trajectory, wound type classification, tissue composition, and paired patient-reported pain and itch scores, is proposed to standardise outcome reporting across future studies.